Then we explore other issues surrounding the oral delivery of biologics, including that future developments into miniaturising these device systems may be necessary to ensure compliance and that not all drugs would be suitable for this kind of administration. The research was done in collaboration with Novo Nordisk and demonstrated that the system could deliver insulin, a GLP-1 receptor analogue, adrenaline and adalimumab, a monoclonal antibody.
However, a fluid dose was more desirable, and in a recent paper published in Nature Biotechnolo g y they displayed the development of a self-orientating gastric autoinjector system able to release a liquid.
To overcome the challenge of size and ensure they could deliver enough drug, they developed solid formulations of biologic drugs, such as insulin. They eventually designed sugar cylinders that had these elements and could be adjusted to control the rate of dissolution and drug release through the needle. They addressed orientation challenges in a paper published two years ago and reviewed materials that could hold energy from a compressed spring, with brittle fracture mechanics, that could sense a humid environment.
#Giovanni traverso how to
how to fit enough drug within a blueberry-sized device, a safe capsule size for oral administration. how to autonomously trigger the drug delivery event/injection, and c. ensuring the sharp needle is always in contact with the desired tissue, b. We went on to discuss his team’s recent work on the development of gastric autoinjectors and how, during the process, they broke it up into three challenges: a. “On the physical side we have actually been able to deliver a very broad set of molecules, including monoclonal antibodies,” stated Giovanni. Physical techniques, he described as those that involve some kind of intervention such as a medical device, eg, a hypodermic needle for injections, or ultrasound at certain frequencies to propel drugs into tissue. While manageable for infrequent treatments, for those who must be injected regularly, such as diabetes patients, being able to simply swallow a pill may seem much more desirable.
Though promising, these therapeutics present several drug delivery challenges, including that their composition makes them liable to damage in the gastrointestinal (GI) tract, requiring them to be delivered intravenously or subcutaneously. His research focuses on the development of next generation drug delivery systems and biomedical devices to support new modes of drug administration.īiologic therapies are growing in popularity, accounting for 13 of the 53 new drugs the US Food and Drug Administration (FDA) approved in 2020. To address such an important topic, we are joined by Giovanni Traverso, Assistant Professor in the Department of Mechanical Engineering at Massachusetts Institute of Technology (MIT), and a gastroenterologist at Brigham and Women’s Hospital (BWH), Harvard Medical School. In this episode, we discuss one of drug delivery’s greatest challenges: how to orally administer biological therapies, such as antibodies and hormones. This relationship is not possible based on lifespan dates.How close are we to oral biologic drug delivery? Will biomedical devices be essential in overcoming drug delivery challenges? Discover all this and more in this podcast with MIT’s Assistant Professor Giovanni Traverso. You have chosen this person to be their own family member. Year should not be greater than current year Continuing with this request will add an alert to the cemetery page and any new volunteers will have the opportunity to fulfill your request. Sorry! There are no volunteers for this cemetery. GREAT NEWS! There is 1 volunteer for this cemetery. This photo was not uploaded because you have already uploaded 15 photos to this memorial This photo was not uploaded because this memorial already has 30 photos This photo was not uploaded because you have already uploaded 5 photos to this memorial This photo was not uploaded because this memorial already has 20 photos You may not upload any more photos to this memorial
0 kommentar(er)
